Uplizna reduces immune B-cell subsets linked to disease activity
Uplizna reduces several subsets of immune B-cells that are linked to relapses in people with neuromyelitis optica spectrum disorder, data show.| Neuromyelitis News
Uplizna reduces several subsets of immune B-cells that are linked to relapses in people with neuromyelitis optica spectrum disorder, data show.| Neuromyelitis News
Symptoms of late-onset NMOSD, occurring in patients over 50, may look like those of a stroke and can delay proper diagnosis and treatment.| Neuromyelitis News
Attacks marked by spinal cord inflammation significantly increase the chance of worse disability in NMOSD and MOGAD, per a study.| Neuromyelitis News
Regular rituximab treatment in neuromyelitis optica spectrum disorder resulted in less disability and fewer relapses, per a real word study.| Neuromyelitis News
Patricia Inacio is a science writer for Neuromyelitis News with a PhD in cell biology. She covers the latest news and information on a variety of NMO topics.| Neuromyelitis News
Depression, anxiety, and sleep disturbances are common among patients with neuromyelitis optica spectrum disorder, a new meta-analysis shows.| Neuromyelitis News
Nearly all neuromyelitis optica spectrum disorder patients who took Enspryng are free from relapses after six months, a Japanese study shows.| Neuromyelitis News
Category archive page for News.| Neuromyelitis News
Immunosuppressive therapy is safe and was found to significantly reduce relapses in elderly patients with late-onset NMOSD, per a study.| Neuromyelitis News
Off-label rituximab significantly reduces the risk of relapse and lessens disability in most NMOSD patients, a long-term study showed.| Neuromyelitis News
